About DLong MedTech
Company profile: Founded in 2024 in Tustin, California, DLong MedTech Inc. is a U.S.-based medical device company developing purpose-built interventional balloon technologies for pulmonary and cardiovascular diseases.
Vision: To shape the future of pulmonary and cardiovascular intervention through purpose-built innovation.
Mission: To address unmet clinical needs in pulmonary and cardiovascular care by developing purpose-built, minimally invasive devices that improve procedural outcomes, expand treatment options, and enhance patients’ quality of life.
Key Highlights
- 3 FDA Breakthrough programs
- 4 U.S. patent applications
- ISO 13485 Quality system under implementation
- U.S. pilot facility
DLong MedTech’s Innovative Products
DLong MedTech is developing a portfolio of purpose-built interventional products for pulmonary and coronary vascular diseases, including balloon dilatation catheters and drug-coated balloons designed to address challenging vascular lesions. Three of our product programs have received FDA Breakthrough Device Designation, reflecting their potential to provide more effective treatment options for patients with serious unmet clinical needs.
FDA Breakthrough Device Designations
DLong MedTech has received three FDA Breakthrough Device Designations across its pulmonary and coronary product programs. These designations recognize the potential of our products to address serious conditions where important unmet clinical needs remain.
Quality Without Compromise
Quality is the foundation of our success. We advance product development through innovation and build trusted medical devices defined by exceptional quality.
Vascular Simulation
Our vascular simulation models recreate complex pulmonary and coronary anatomies to support product development, performance evaluation, and procedural planning. They also provide a practical platform for internal and external training in vascular intervention techniques.
Clinical Needs
Complex pulmonary and coronary vascular diseases remain difficult to treat because of challenging anatomy, limited device options, restenosis, and the long-term risks of permanent implants. These unmet needs are especially significant in the following disease areas:
- Small-vessel disease
- Coronary bifurcation lesions
- Chronic Thromboembolic Pulmonary Hypertension (CTEPH)
- Pulmonary artery stenosis
Advanced Technology Platform
DLong MedTech is building an integrated technology platform spanning drug-coated balloon delivery, device-coating technologies, and vascular procedure simulation. This platform supports the development of differentiated solutions for complex pulmonary and coronary vascular diseases.
Drug-Coated Balloon Technology
A versatile balloon and drug-coated balloon technology platform designed to advance treatment options for complex pulmonary and coronary vascular diseases.
Vascular Simulation Technology
Our experienced team brings skill and passion to every project, no matter the size.
Vascular Device Engineering Capability
Purpose-built balloon and catheter designs developed for challenging vascular anatomy and interventional procedures.